AAMU
VIRX

Amundi Asset Management US’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Amundi Asset Management US’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-637
Closed -$45K – 1677
2018
Q3 		$45K Hold
637
– – ﹤0.01% 1566
2018
Q2 		$47K Buy
+637
New +$56.7K ﹤0.01% 1517

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Amundi Asset Management US's VIRX Position: Q4 2018 in Review

Amundi Asset Management US sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2018, closing a stake of 637 shares — an estimated $45K sold.

Amundi Asset Management US first reported a position in VIRX in Q2 2018 and held it in 2 quarters. The position peaked at $47K in Q2 2018. 40 funds tracked by Wall St. Rank hold VIRX as of Q4 2018.

  • Amundi Asset Management US reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 637 Viracta Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $45K.
  • Amundi Asset Management US first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Amundi Asset Management US's Viracta Therapeutics, Inc. Common Stock position peaked at $47K in Q2 2018.
  • 40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.